Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Hormone Resistant Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT01468532
What this trial is testing

Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Barbara Ann Karmanos Cancer Institute 18
Early research (Phase 1)WithdrawnNCT00937417
What this trial is testing

S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors

Who this might be right for
Breast CancerHead and Neck CancerLung Cancer+2 more
SWOG Cancer Research Network
Large-scale testing (Phase 3)Study completedNCT00554229
What this trial is testing

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases

Who this might be right for
Prostate Cancer
AstraZeneca 896
Testing effectiveness (Phase 2)Ended earlyNCT05551117
What this trial is testing

Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors

Who this might be right for
Castration-Resistant Prostatic CancerAndrogen-Independent Prostatic CancerAndrogen-Insensitive Prostatic Cancer+14 more
MacroGenics 192
Testing effectiveness (Phase 2)Study completedNCT02097303
What this trial is testing

Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

Who this might be right for
Prostate Cancer
Carolina Research Professionals, LLC 36
Testing effectiveness (Phase 2)Ended earlyNCT02985021
What this trial is testing

Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies

Who this might be right for
Hormone-Resistant Prostate CancerMetastatic Prostate CarcinomaRecurrent Prostate Carcinoma+1 more
Seattle Institute for Biomedical and Clinical Research 2
Large-scale testing (Phase 3)UnknownNCT01949337
What this trial is testing

Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Alliance for Clinical Trials in Oncology 1,311
Large-scale testing (Phase 3)Active Not RecruitingNCT06551324
What this trial is testing

Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1).

Who this might be right for
Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Pfizer 600
Early research (Phase 1)Looking for participantsNCT05818683
What this trial is testing

Pasritamig (JNJ-78278343) in Combination With Other Agents for Metastatic Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate NeoplasmsMetastatic Hormone-sensitive Prostate Cancer
Janssen Research & Development, LLC 300
Early research (Phase 1)Active Not RecruitingNCT06229366
What this trial is testing

[Ac-225]-PSMA-62 Trial in Oligometastatic Hormone Sensitive and Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Prostate CancerMetastatic Castration-resistant Prostate CancerOligometastatic Prostate Carcinoma+1 more
Eli Lilly and Company 142
Testing effectiveness (Phase 2)Study completedNCT01309672
What this trial is testing

S1014 Abiraterone Acetate in Treating Patients With Prostate Cancer Who Have Undergone Initial Hormone Therapy

Who this might be right for
Prostate Cancer
SWOG Cancer Research Network 41
Testing effectiveness (Phase 2)Study completedNCT00878436
What this trial is testing

Safety and Efficacy Studies of Panobinostat and Bicalutamide in Patients With Recurrent Prostate Cancer After Castration

Who this might be right for
Prostate CancerProstatic Neoplasms
NYU Langone Health 52
Testing effectiveness (Phase 2)Study completedNCT01848067
What this trial is testing

Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 9
Testing effectiveness (Phase 2)Ended earlyNCT01828476
What this trial is testing

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Who this might be right for
Prostate Cancer
Rutgers, The State University of New Jersey 13
Testing effectiveness (Phase 2)WithdrawnNCT01478308
What this trial is testing

Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
New Mexico Cancer Research Alliance
Testing effectiveness (Phase 2)Study completedNCT01498978
What this trial is testing

Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Adenocarcinoma of the ProstateHormone-resistant Prostate CancerRecurrent Prostate Cancer+1 more
OHSU Knight Cancer Institute 10
Early research (Phase 1)Study completedNCT00510718
What this trial is testing

MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer

Who this might be right for
Prostate CancerHormone Refractory Prostate Cancer
Pfizer 140
Testing effectiveness (Phase 2)Ended earlyNCT02844582
What this trial is testing

Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Who this might be right for
Hormone-Resistant Prostate CancerStage IV Prostate Adenocarcinoma
University of California, Davis 2
Testing effectiveness (Phase 2)Study completedNCT02601014
What this trial is testing

Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7

Who this might be right for
Prostate CancerRecurrent Prostate CarcinomaStage IV Prostate Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 32
Testing effectiveness (Phase 2)Study completedNCT01487720
What this trial is testing

GEMOX in Docetaxel-Refractory Castration-Resistant Prostate Cancer

Who this might be right for
Prostate Cancer
Asan Medical Center 33
Next Page